Chronic Myeloid Leukemia Coverage from Every Angle
Advertisement
Advertisement

Jorge E. Cortes, MD, on Ponatinib in Patients with Chronic-Phase CML: The OPTIC Trial

Posted: Tuesday, December 15, 2020

Jorge E. Cortes, MD, of the Georgia Cancer Center at Augusta University, discusses the OPTIC trial, which compared treatment outcomes by mutation status and three starting doses of ponatinib for patients with chronic-phase CML. He offers clinical pearls on side effects and balancing the benefits and risks in this challenging treatment setting.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.